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Abstract: Cluster headache (CH), a severe primary headache, is often misdiagnosed and 
mismanaged. The aim of this study was to develop and evaluate a screening tool to aid the diagnosis 
of CH. We developed a novel 12-item screening tool. This was comprised of four components: (1) 
images depicting headache pain; (2) pain descriptors; (3) key questions that could differentiate 
between CH and migraine; and (4) a visual analogue pain scale. The total possible questionnaire 
score ranged from 3-32. Patients with CH and migraines (control group) were recruited 
prospectively from a headache centre in the North of England, UK. Two-hundred and ninety-six 
patients were included in the study: 81 CH patients, 36 of which suffer with episodic CH and 45 
with chronic CH; 215 migraine patients, 92 of which suffer with episodic migraine and 123 with 
chronic migraine. The mean questionnaire score was higher in CH patients versus migraine patients 
(28.4 versus 19.5). At a cut-off score of >25 out of 32, the screening tool had a sensitivity of 86.4% 
and a specificity of 92.0% in differentiating between CH and migraine. The screening tool could be 
a useful instrument to aid the diagnosis of a CH. The images depicting headache pain do not clearly 
discriminate between CH and migraine. 
Keywords: migraine; images; drawings; questionnaire; sensitivity; specificity; survey; intervention 
development 
 
1. Introduction 
A cluster headache (CH) is a severe primary headache with a prevalence of approximately 0.1% 
[1]. CH patients incur a high healthcare cost, estimated in the USA as greater than $2.8 billion/year 
[2]. CH is characterised by trigeminal distribution of pain, cranial autonomic symptoms and circadian 
and circannual periodicity [3]. Research indicates that the most common misdiagnosis of CH is 
migraine [4–8]. Although CH has very distinct clinical features, patients often face delay in diagnosis, 
misdiagnosis, and mismanagement [6,8–11]. It is important that CH is diagnosed early as effective 
therapies exist and should be recommended [12]. Misdiagnosis could be avoided if healthcare 
professionals (such as primary care practitioners, clinicians in secondary and emergency care) are 
aware of the striking differences between the clinical presentation of CH and that of migraine. Despite 
the significant disability and impact on quality of life associated with CH, patients are often in a 
diagnostic limbo for many years, living with debilitating, severely painful attacks, before a correct 
diagnosis is made [13]. Misdiagnosis of CH has a significant impact on patients’ daily life, 
employment, and mental health [14]. Sick leave is high among CH patients [15]. A correct and timely 
diagnosis will improve the quality of life, will avoid unnecessary consultations and referrals, and, as 
a consequence, will reduce the financial and human health resource burden on the healthcare system 
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[13]. Even though the diagnostic delays of CH have decreased over the past decades [16], the 
timeframe between the onset of the disease and first consultation at a headache centre is still high [9]. 
Despite significant advances in our understanding of CH pathophysiology [17–19] and 
treatment [20,21], the way CH is diagnosed remains unchanged [3]. To date, since there are no 
available biological markers to diagnose CH [3], the diagnosis is entirely based on the clinical history. 
The lack of knowledge of CH’s clinical characteristics could lead to incomplete history taking and the 
misdiagnosis of CH. There is a need for a screening tool to aid healthcare professionals to recognise 
CH. A pilot study by our research team, for which we developed a screening tool with six images 
depicting headache pain, demonstrated the potential of using visual aids to detect headache severity 
[22]. Here, we report the results of our large study in which we tested a screening tool for CH.  
The aim of this study was to determine the overall performance of a screening tool and the 
performance of each item in the tool in differentiating between CH and migraine. We also aimed to 
determine the performance of images depicting headache pain in discriminating between CH and 
migraine.  
2. Materials and Methods 
2.1. Study Design 
This is a prospective case-control study, evaluating a newly developed 12-item self-administered 
questionnaire. The study included patients with CH (the study group) and a group of patients with 
migraines (control group).  
2.2. Study Population 
All patients were recruited prospectively from a headache centre in the north of England, UK, 
between October 2017 and March 2019. Patients older than 18 who received a prior diagnosis of CH 
or migraine based on the ICHD-3b criteria [23] were invited to participate by A.B. and F.A. Patients 
with a dual diagnosis of CH and migraine were excluded from the study. 
2.3. Ethics 
This study has received ethical approvals from the local University Research Ethics Committee 
(reference no: 1613/27.09.2016) and from the Health and Social Care Research Ethics Committee (HSC 
REC) (reference no: 16/NI/0269). All patients provided written informed consent to participate. The 
patients completed the questionnaire un-aided.  
2.4. Screening Tool Development 
The screening tool comprised of four main components: (1) screening tool with six images 
depicting headache pain (Figure 1) [22]; (2) verbal description of pain; (3) key questions that could 
differentiate between CH and migraine; and (4) a visual analogue scale. The images used in the first 
component were inspired on real life pictures and artistic renditions of headache available online [24–
27]. Image ‘a‘ was inspired on a piece of artwork by Agnes-Cecile for Arte Cluster [22,24,25], and 
Image ‘e’ was inspired on art created by Faderhead for Deviant Art (Figure 1) [27]. The methodology 
on how we developed this screening tool with six images depicting headache pain severity has been 
published [22]. Healthy participants rated image ‘d’ and image ‘e’ as excruciating, image ‘b’ as severe, 
image ‘c’ as severe/moderate, and image ‘f’ as depicting mild pain [22]. The International 
Classification of Headache Disorders-3b (ICHD-3b) [23] criteria and the patients’ description of pain 
in the Cluster Headache: Impact and Perception Study (CHIPS) [28] were used to determine the 
verbal description of pain, which included categories such as the intensity of the pain (mild, 
moderate, severe, very severe, excruciating), the nature of the pain (pressure, throbbing, stabbing, 
burning), and a description of the pain (red hot poker in the eye, pounding heart in the head) [29]. 
The key questions were provided by 10 UK-based headache specialists, members of the British 
Association for the Study of Headache (BASH) [30,31]. The headache experts were invited to 
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participate via email. They were asked to provide questions that they thought were able to 
differentiate between CH and migraine during a clinical consultation. The most asked questions 
provided by the headache specialists were included in the screening tool.  
  
Image a Image b 
 
 
Image c Image d 
  
Image e Image f 
Figure 1. Images depicting different pain severities. 
The questionnaire was pilot tested on patients with CH and migraine. Concerns were raised by 
the patients with migraine as to whether they should report their mild headaches or migraine attacks. 
To avoid confusion, the questionnaire was customised based on diagnosis (i.e., ‘Please choose one 
image that best illustrates your cluster headache attacks?’ versus ‘Please choose one image that best 
illustrates your migraines?’) (see Supplementary File).  
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2.5. Statistical Methodology 
Analysis 
The dataset was analysed via descriptive analysis [32]. The frequency distribution (counts and 
percentages) of the categories within each of the 12 variables used to evaluate the performance of the 
screening tool were summarised for each group of patients. The test scores were coded numerically 
as defined in Table 1. Higher scores were given for test items characteristic for CH. A dichotomous 
scale (no = 0; yes = 1) was used for the test items with binary responses (restlessness, excruciating 
agony, headache at specific times, strictly unilateral pain, ipsilateral cranial autonomic symptoms). 
Test items for the severity of pain were coded as follows: image preference (f = 1 (least severe); a = 2; 
c = 3; b = 4; e = 5; d = 6 (most severe)) [22], the pain scale (scores from zero to ten), and the intensity of 
pain (mild = 1; moderate = 2; severe = 3; very severe = 4; excruciating = 5). The description of pain as 
a ‘red hot poker in the eye’, which is usually attributed to CH [29], was coded with 1, whilst a 
‘pounding heart in the head/other’ was coded with 0. A ‘stabbing/burning’ pain that describes CH 
[33] was coded with 3, while ‘pressure’ was coded with 2, and ‘throbbing/other’ with 1. The attack 
duration of ≤ 3 hours, which characterises CH, was coded with 1, whilst the attack duration > 3 hours 
was coded with 0. A total score was determined by adding up the scores for the 12 items in the 
screening tool [34]. The total score was analysed to evaluate the overall performance of the screening 
tool. Table 2 shows that the minimum possible total score = 3, and the maximum possible total score 
= 32. The descriptive statistics (mean ± 95% CI) of the total score were compared between each group 
of patients. 
Table 1. Variables measured with the 12-item screening tool. 
Question Variable  Coded test scores 
1. Please choose one image that 
best illustrates the most severe 
headache you have experienced  
Image preference f = 1 (least severe); a = 2; c = 3; b = 4; e 
= 5; d = 6 (most severe) 
2. Please mark with an X the 
intensity of your pain on the scale 
below 
Pain scale  Scores from zero to ten 
(0 = No pain; 5 = Moderate pain; 10 = 
Worst possible pain) 
3. Please choose only one option 
from the following list that 
describes your headaches 
Intensity  Mild = 1; Moderate = 2; Severe = 3; 
Very Severe = 4; Excruciating = 5 
4. Please choose only one option 
from the following list that 
describes your headaches 
Nature of pain Throbbing/Other = 1; Pressure = 2; 
Stabbing/Burning = 3 
5. Please choose only one option 
from the following list that 
describes your headaches 
Description of pain Red hot poker in the eye = 1;  
Pounding heart in the head/Other = 
0 
6. Do you feel restless during the 
headache attack? 
Restlessness No = 0; Yes = 1 
 
7. Is the pain ‘excruciating agony’? Excruciating agony No = 0; Yes = 1 
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8. Does the pain wake you up from 
sleep the same time each night/ or 
attack comes at a specific time of 
the day? 
Headache at specific times No = 0; Yes = 1 
 
9. Is the pain strictly on one side? Strictly unilateral pain No = 0; Yes = 1 
10. Ipsilateral cranial autonomic 
symptoms (e.g., red watery eyes 
and/or runny nose?) 
Ipsilateral cranial 
autonomic symptoms 
No = 0; Yes = 1 
 
11. How long does the most severe 
pain last for with medication? 
Treated attack duration > 3 hours = 0; ≤ 3 hours = 1; 
12. How long does the most severe 
pain last for without medication? 
Untreated attack duration > 3 hours = 0; ≤ 3 hours = 1;  
Table 2. Computation of the total score. 
Variable Minimum Maximum 
1 Image preference 1 6 
2 Pain scale 0 10 
3 Intensity  1 5 
4 Nature of pain 1 3 
5 Description of pain 0 1 
6 Restlessness 0 1 
7 Excruciating agony 0 1 
8 Headache at specific times 0 1 
9 Strictly unilateral pain 0 1 
10 Ipsilateral cranial autonomic symptoms 0 1 
11 Treated attack duration ≤ 3h 0 1 
12 Untreated attack duration ≤ 3h 0 1 
Total Score 3 32 
2.6. Sensitivity and Specificity and the Receiver Operating Characteristics (ROC) 
Specificity, sensitivity, false positive rate, false negative rate, positive and negative predictive 
values, and positive and negative likelihood ratios were calculated for the items with dichotomous 
responses [35]. Descriptive statistics (mean and 95% confidence intervals) and ROC curve statistics 
were computed to determine how the total scores could be interpreted to distinguish between 
patients diagnosed with CH versus migraine [36]. The ROC curve also permitted the identification 
of a cut-off test score that best distinguished between patients with CH and migraine. This cut-off 
test score was indicated by the inflection point on the ROC curve that was closest to the top left corner 
[37]. We also performed gender segregated analysis as follows: we separated the data set into male 
and females. For females, we performed class balancing to equalise the number of occurrences of CH 
and migraine. For males, we did not perform balancing as the data set is approximately balanced. A 
total sample size of about 300 subjects is generally required to provide accurate estimates for 
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sensitivity and specificity for most screening or diagnostic tests involving two groups of patients, 
among which a specified disease is either present or absent [38]. The analysis was performed using 
the software R version 3.5.1. 
3. Results 
3.1. Description of the Sample  
The sample consisted of 296 patients, which were classified into the following two groups: the 
case group and the control group. The case group consisted of patients diagnosed with CH (n = 81, 
27.4%), of whom 45 patients were diagnosed with chronic CH (55.6%) and 36 with episodic CH 
(44.4%). The control group consisted of patients with migraine (n = 215, 72.6%), of whom 123 were 
patients with chronic migraine (57.2%) and 92 patients with episodic migraine (42.8%). The ages of 
the patients ranged from 18 to 79 years (mean = 43.8; 95% CI = 42.3, 45.6). Patients with CH had a 
mean age of 46.06 (95% CI = 43.18, 44.94) and patients with migraine had a mean age of 42.93 (95% CI 
= 41.02; 44.83). The CH group was comprised of 51 males and 30 females (male:female ratio: 1:7) 
whilst the migraine group consisted of 35 males and 180 females (female:male ratio: 5:14). The females 
had a mean age of 42.8 (95% CI 41; 44.7) whilst males had a mean age of 46 (95% CI 42.9; 49.1). 
3.2. Descriptive Analysis of Test Scores 
Table 3 summarizes the frequency distributions of the test scores classified by diagnosis. The 
image preference with the highest frequency was image ‘d’ for CH (61.9%); whereas image ‘b’ (21.5%) 
and image ‘c’ (23.3%) were the highest frequencies for migraine. Image ‘d’ was rated as showing 
excruciating pain by most healthy participants in a study by our research team, while image ‘c’ was 
rated as moderate/severe and image ‘b’ as severe [22]. 
Table 3. Frequency distribution of the test scores classified by diagnosis. 
Test item Category 
% within Diagnosis  
Case Group Control Group 
CH 
(n = 81) 
Migraine 
(n = 215) 
Image preference a 4.7 18.9 
b 10.8 21.5 
c 3.9 23.3 
d 61.9 18.0 
e 8.3 7.4 
f 10.3 14.3 
Pain scale 1 0.0 0.0 
2 0.0 0.0 
3 0.0 1.6 
4 0.0 2.0 
5 1.1 3.1 
6 0.0 5.4 
7 3.3 15.8 
8 3.6 33.8 
9 28.0 20.2 
10 63.9 19.9 
Intensity of pain Mild 0.0 1.1 
Moderate 0.0 13.8 
Severe 7.8 35.0 
Very severe 8.6 33.6 
Excruciating 83.6 16.4 
Nature of pain Throbbing/ 
Other 
18.0 40.0 
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Pressure 14.1 33.2 
Stabbing/ 
Burning 
67.8 26.7 
Treated attack duration ≤ 3 hours 100.0 24.3 
> 3 hours 0.0 75.7 
Untreated attack duration  ≤ 3 hours 100.0 0.0 
> 3 hours 0.0 100.0 
Description of pain Pounding 
heart/other 
30.8 84.4 
Red hot poker in 
the eye 
69.2 15.6 
Restlessness No 10 56.7 
Yes 90.0 43.2 
Excruciating agony No 10 56.7 
Yes 90.0 43.2 
Attacks at specific times No 39.1 80.6 
Yes 60.8 19.4 
Strictly unilateral pain No 13.3 55.5 
Yes 86.6 44.5 
Ipsilateral cranial 
autonomic symptoms 
No 3.6 57.8 
Yes 96.4 42.2 
Key findings are highlighted in bold. 
The description of pain with the highest frequency was ‘red hot poker in the eye’ for patients 
diagnosed with CH (69.2 %), whereas ‘pounding heart in head/other’ was the highest frequency for 
patients diagnosed with migraine (84.4%). Most patients diagnosed with CH (90%) reported the 
presence of restlessness during the attacks, compared to less than half of the patients with migraine 
(43.2%). 
Most patients diagnosed with CH (96.4%) reported the presence of ‘ipsilateral cranial autonomic 
symptoms’, whereas most patients diagnosed with migraine (57.8%) reported the absence of 
‘ipsilateral cranial autonomic symptoms’.  
3.3. Sensitivity and Specificity of the Test Scores 
Table 4 shows the sensitivity and specificity statistics for the eight test items that used 
dichotomous responses.
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Table 4. Sensitivity and specificity statistics for items with dichotomous responses. 1 
Test item Sensitivity 
 % (CI) 
Specificity 
% (CI) 
PPV 
% (CI) 
NPV 
% (CI) 
FPR 
% (CI) 
FNR 
% (CI) 
Description of pain 68 (58;78) 84 (79;89) 62 (52;72) 87 (83;92) 16 (11;21) 32 (22;38) 
Presence of restlessness 90 (84;97) 56 (50;63) 44 (36;51) 94 (90;98) 44 (37;50) 10 (3;15) 
Excruciating agony 93 (87;98) 33 (27;40) 34 (28;41) 92 (86;98) 67 (60;73)  7 (2;13) 
Attacks at specific times 60 (50;71) 81 (76;86) 54 (44;65) 84 (80;89) 19 (14;24) 40 (29;46) 
Strictly unilateral pain 86 (79;94) 56 (49;62) 42 (35;50) 92 (87;96) 44 (38;51) 14 (6;19) 
Ipsilateral cranial autonomic symptoms 96 (92;100) 57 (50;63) 46 (38;53) 98 (95;100) 43 (37;50)  4 (0.0;7) 
Treated attack duration ≤3h 100 (100;100) 77 (71;82) 62 (54;70) 100 (100;100) 23 (18;29) 0 (0.0;0.0) 
Untreated attack duration ≤3h 100 (100;100) 100 (100;100) 100 (100;100) 100 (100;100) 0 (0.0;0.0) 0 (0.0;0.0) 
PPV: positive predictive value; NPV: negative predictive value; FPR: false positive rate; FNR: false negative rate; CI: 95% confidence interval.2 
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The presence of ‘ipsilateral cranial autonomic symptoms’ had a high sensitivity (96%) but a 
moderate false positive rate (43%). ‘Excruciating agony’ also had a high sensitivity (93%) but a higher 
false positive rate (67%). ‘Restlessness’ was a symptom with high sensitivity (90%) and a moderate 
false positive rate (44%). ‘Strictly unilateral attacks’ had a high specificity (86%) and a moderate false 
positive rate (44%). The ‘Description of pain’ had a lower level of sensitivity (68%) than the other 
symptoms, but it also had a lower false positive rate (16%). ‘Headaches at specific times’ had a low 
sensitivity (60%) but also with a low false positive rate (19%).  
3.4. ROC Analysis for Whole Data Set 
Figure 2 illustrates the ROC curves for ‘Image preference’, ‘Pain scale’, ‘Intensity of pain’, 
‘Nature of pain’, and ‘Total score’. The areas under all of the ROC curves were >0.5 (p < 0.001), 
implying that the specified variables significantly distinguished between patients with CH and 
patients with migraine. None of the tests were worthless. The ROC curves also permitted the 
identification of cut-off test scores that best distinguished between patients with CH and patients 
with migraine. The cut-off scores are identified in Table 5. Based on the area under the curve (AUC), 
the most accurate test was ‘Total score’ (0.955 = good); followed in order of magnitude by ‘Intensity 
of pain’ (0.841 = good); ‘Pain scale’ (0.799 = fair); ‘Image preference’ (0.723 = fair); and ‘Nature of pain’ 
(0.702 = fair). The ‘Total score’ for the 12 items appeared to provide a more accurate method to 
distinguish between patients with CH and patients with migraine than the separate scores for ‘Image 
Preference’, ‘Pain scale’, ‘Intensity of pain’, and ‘Nature of pain’. When the images are removed, the 
‘Total score’ is a more accurate test (sensitivity 92.6%, specificity 93.9%) than the ‘Total score’ of the 
12 items (sensitivity 86.4%, specificity 92.0%). Patients with CH had a higher mean score (28.4; 95% 
CI 27.7; 29, 1) compared to patients with migraine (19.5; 95% CI 19; 20). 
 
Figure 2. Receiver Operating Characteristics (ROC) curves for whole data set. The area under the 
curve (AUC) Total score = 0.955; Total score (no images) = 0.979; AUC Intensity = 0.841; AUC Pain 
scale = 0.799; AUC Image preference = 0.723; AUC Nature of pain = 0.702; AUC; area under the ROC 
curve is significantly greater than 0.5 (p < 0.001). 
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Table 5. Cut-off points on the ROC curves for whole data set. 
Test Item Cut-off Sensitivity (%) Specificity (%) 
Nature of pain 3 (Stabbing/Burning) 67.9 73.0 
Image preference 5 (Image ‘e’) 70.3 73.0 
Intensity of pain 5 (Excruciating) 82.7 82.7 
Pain scale 9 (out of 10) 83.9 67.9 
Total score 25 (out of 32) 86.4 92.0 
Total score (no images) 20.5 (out of 32) 92.6 93.9 
3.5. ROC Analysis According to Gender 
Figure 3 shows the ROC curves according to gender. The cut-off points on the ROC curves are 
presented in Table 6. Similar to the analysis including the whole data set, the ‘Total score’ is the most 
precise test in differentiating CH from migraine. The ‘Total score’ >23 (out of 32) has a high 
performance (sensitivity 90.1%, specificity 94.2%) in detecting males with CH. The ‘Total score’ >25/32 
has a lower sensitivity in detecting females with CH (sensitivity 90.0%, specificity 91.6%). Without 
the images, the ‘Total score’ has a slightly better performance than the ‘Total score’ of the 12-items 
for both male and female groups. The intensity of pain ‘excruciating’ has a higher specificity in 
detecting males with CH (91.4%) than females (81.1%). The image preference has a higher 
performance in detecting females (sensitivity 73.3%, specificity 79.4%) than males with CH 
(sensitivity 66.6%, specificity 77.1%).  
 
(a) ROC curve for the male group (b) ROC curve for the female group 
Figure 3. ROC curves according to gender. The AUC male group: AUC Total score = 0.977; AUC Total 
score (no images) = 0.979; AUC Intensity = 0.881; AUC Pain scale = 0.852; AUC Image preference = 
0.751; AUC Nature of pain = 0.640. 
The AUC female group: AUC Total score = 0.948; AUC Total score (no images) = 0.975; AUC 
Intensity = 0.838; AUC Pain scale = 0.795; AUC Image preference = 0.726; AUC Nature of pain = 0.761. 
The area under the ROC curve is significantly greater than 0.5 (p < 0.001). 
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Table 6. ROC cut-off points for the male and female groups. 
Statistics according 
to Gender 
Nature 
of Pain 
Image 
Preference 
Intensity 
of Pain 
Pain Scale Total Score Total Score 
(without 
Images) 
Cut off  Male 3  5 5 9 23.6/32 20/32 
Female 3 6 5 9 25.0/32 20.5/32 
Sensitivity 
(%)  
Male 60.7 66.6 80.3 84.3 90.1 94.1 
Female 80.0 73.3 86.6 83.3 90.0 93.3 
Specificity 
(%) 
Male 68.5 77.1 91.4 77.1 94.2 94.2 
Female 73.8 79.4 81.1 66.1 91.6 93.3 
Nature of pain 3 = Stabbing/burning; Image preference 5 = Image ‘e’; Image preference = Image ‘d’; 
Intensity of pain 5 = Excruciating; Pain scale 9 (out of 10). 
3.6. ROC Analysis with Class Balancing 
To evaluate the influence of the unbalanced classes on the statistical analysis in Figure 2 and 
Figure 3 we performed ROC analysis with class balancing. The data set is unbalanced in two ways: 
more females than males and more occurrences of migraines than CH are in the data set. Figure 4 
shows the mean ROC curve and associated 95% CI of the ‘Total score’ for the whole data set and for 
the female group, respectively, after class balancing. Balancing was performed by gathering 10 
random under-samplings of the occurrences of migraine from the complete data set, including both 
males and females. The ROC curve for each realization of the random under-sampling were averaged 
to obtain the presented ROC curves. Class balancing does not alter the characteristics of the ROC 
curve.  
  
(a) Whole data set (b) Female group 
Figure 4. ROC curve of the ‘Total score’ after class balancing. 
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4. Discussion 
In this study, we developed a self-administered screening questionnaire for CH. The main 
objectives of this study were to determine the overall performance of the questionnaire and the 
performance of the test items that best discriminate between CH and migraine. The results were 
interpreted assuming that a screening test should ideally exhibit a high level of sensitivity (to detect 
as many true positives as possible). 
4.1. Clinical Indicators of CH versus Migraine 
Current research indicates that the key differences between CH and migraine are the severity of 
pain, restlessness behaviour during attacks [3], and prominent ipsilateral cranial autonomic 
symptoms [39]. CH is often described in the literature as the ‘most severe pain known to man’ [28,40–
42]. Such a pain descriptor is not usually attributed to migraines [43]. The attacks described like an 
‘excruciating agony’ in our study proved to have a low specificity (33%). Although ‘excruciating 
agony’ had a high sensitivity (93%) in detecting CH, almost half of the patients with migraine (43%) 
chose this descriptor of pain. Therefore, the descriptor ‘excruciating’ might not apply only to CH 
patients [40] but also describes the severity of migraine attacks, as shown by our study. The descriptor 
of pain ‘excruciating agony’ is not a good discriminator between CH and migraine, according to our 
questionnaire study. When patients had to choose the intensity of pain from mild to excruciating, this 
descriptor of pain was a more accurate test (sensitivity 82.7%, specificity 82.7%). This highlights the 
importance of question phrasing that could influence the pain information provided [44]. 
Furthermore, pain reporting is subjected to multiple biases. In a stressful situation, recall of pain 
intensity is exaggerated and also chronic pain is itself associated with an overestimation of pain 
intensity [45]. Additionally, associated psychiatric co-morbidities could have an influence on how 
pain is reported [46]. The self-report of physical pain can be subjected to recollection bias [45,47]. 
Patients with CH overestimated the severity of retrospective attacks compared to the attacks recorded 
prospectively [48].  
It is known from the literature that CH has very characteristic clinical features: restlessness 
during attacks and ipsilateral autonomic cranial symptoms [3]. These clinical characteristics had a 
high sensitivity (>90%) but with low specificity (<60%) which meant they were present in nearly all 
patients with CH and also present in many patients with migraine. Previous studies report variable 
results for the presence of restlessness during CH attacks (80% [49], 67.9% [10], 51% [50]). This could 
be due to differences in question phrasing even though the questionnaires used for data collection 
were not published [10,49,50]. According to previous reports, the presence of restlessness had a 
higher sensitivity in patients with chronic CH (sensitivity 100%, specificity 90%) than episodic CH 
(sensitivity 82%, specificity 92%) [51]. Although the cranial autonomic symptoms have been reported 
in 56% of patients with migraine, they are less severe, usually bilateral and inconsistent from one 
attack to the other [39]. In contrast, the cranial autonomic symptoms reported in 94% of patients with 
CH are severe, unilateral, and consistently present from one attack to the other [39]. In our study, the 
presence of ipsilateral cranial autonomic symptoms were reported in 96.4% of patients with CH and 
42.2% of patients with migraine, similar to previous reports [39].  
More research is required to identify the descriptors of pain that best differentiate between CH 
and migraine. Untreated attack duration (3 hours) was the test item with the highest sensitivity 
(100%) and specificity (100%). Previous reports showed similar findings [51–53]. According to 
previous studies, the untreated attack duration of ≤3 hours is one of the best clinical features to 
discriminate between CH and other primary headaches [51–53]. However, this is the result of strictly 
applying the ICHD-3b criteria [3], where CH patients with attacks longer than 3 hours are excluded 
from the research studies. This study showed many overlapping features between CH and migraine 
which could account for diagnostic delays and misdiagnosis. There is no single test item that can 
differentiate between the two conditions. However, the total screening tool score with a cut-off > 
25/32 was highly sensitive (86.4%) and specific (92.0%) in differentiating CH from migraine. This tool 
is designed as a screening instrument, and further confirmation of diagnosis from a specialist is 
required. 
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4.2. Screening Tools for CH 
Multiple proposals have been made for screening and diagnostic tools for CH [34,52]. A 
screening tool with 8-items was found to have a high sensitivity (95%) and specificity (96%) in 
detecting CH [34]. This study, which included 42 patients with CH, of whom one patient had chronic 
CH, should be repeated in a higher population of patients with chronic CH to avoid selection bias 
[34]. A lengthy 142-item web based questionnaire was tested in a large population of 437 patients 
with self-reported CH [52]. Three questions were identified to predict CH: untreated attack duration 
of 15 to 180 min, an attack free period of four months to three years, and the male gender (sensitivity 
53.8%, specificity 88.9%, positive predictive value 95.5%, and negative predictive value 30.8% [52]). 
The three-item questionnaire was not independently tested and the study did not include a control 
group [52]. Fritsche et al. tested a 20-item German language questionnaire to diagnose migraine, 
tension type headache, and trigeminal autonomic cephalalgias (TACs) in a tertiary headache centre 
[54]. The exact types of TACs are not specified and therefore the number of diagnosed CH cases is 
unknown [54]. The same questionnaire developed by Fritsche et al. was tested in a general population 
with headache by Yoon et al. [55] and Kukava et al. [56]. An analysis algorythm based on the ICHD 
criteria was used to diagnose different types of headaches, but the algorythm details were not 
provided [54]. The questionnaire proved to be more useful at detecting a migraine and tension type 
headache and it overdiagnosed patients with CH [54].  
4.3. Images Depicting Headache Pain 
Pain experience involves a complex relationship between sensory and emotional factors [57]. 
The diagnosis process is usually focused on the sensory experience of pain while the emotional 
factors are neglected [58]. Images depicting headache pain are a more complex representation of the 
pain experience as they also capture the affective aspect of pain [59]. This study showed that images 
with a higher intensity (image ‘e’ and image ‘d’) could differentiate between CH and migraine but 
the performance was moderate (sensitivity 70.3%, specificity 73%). Images are more precise in 
detecting females than males with CH. This could be due to several biases related to pain reporting 
as mentioned above [45,46]. Overall, the images depicting headache pain have a low influence in 
detecting a cluster headache. Although the intensity of pain captured via visual analogue scale and 
the intensity from mild to excruciating are more accurate tests than the images in detecting headache 
severity, they have a moderate specificity in detecting CH. This could imply that the intensity of pain 
is not a good differentiator between the two conditions. Other images with different artistic 
characteristics might have a higher performance in distinguishing between CH and migraine. 
Additionally, future research should capture the emotional responses evoked by images depicting 
headache pain in order to better understand their role in the diagnosis of primary headaches. This 
study is the first step in the development and validation of a screening tool for CH. As this tool was 
tested in a headache centre on patients who already received a diagnosis, it requires evaluation in 
other clinical settings, including primary care, before a diagnosis is made. A shorter screening tool 
should be validated, including items that best differentiated between CH and migraine according to 
this study.  
4.4. Strengths and Limitations 
The strength of our study consists in a large sample size and the inclusion of a control group of 
migraine patients, the most common misdiagnosis of CH [38]. This study opens a new field of 
research as it is the first study of its kind to test the usefulness of images depicting headache pain in 
the detection of CH, although the images in this study do not clearly differentiate between CH and 
migraine. The present study was subjected to limitations. The patients were recruited from a 
headache centre after they received a diagnosis of CH or migraine, which may have resulted in a 
selection bias of the enrolled patients. This study lays the foundation for the validation of the 
screening tool, which requires further evaluation in population-based studies. A single centre study 
is another limitation and it should be reproduced in other clinical settings. This study may have been 
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subjected to recall bias, a limitation of all questionnaire studies. Our study was based on the ICHD-
3b criteria, which included the recently deleted symptoms (fullness in the ear, facial and forehead 
flushing) from the ICHD-3 criteria and extending the maximum remission periods of chronic CH to 
up to three months. Although there was no difference in reporting ipsilateral ear fullness and facial 
flushing between patients who received a diagnosis of CH and patients who did not [60], the 
screening tool needs to be evaluated with the current ICHD-3 criteria.  
5. Conclusions 
This is the first study of its kind to develop a screening tool with images depicting headache 
pain to aid the diagnosis of CH. The overall tool score could be a good instrument in the screening of 
CH. Images depicting headache pain do not clearly discriminate between CH and migraine. Our 
study also provides valuable insight into what problems clinicians may be facing in real life to explain 
the delay in diagnosis. 
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